GSK(GSK) Prnewswire·2025-02-27 10:45Core Viewpoint - GSK plc is facing a class action lawsuit due to allegations of misleading statements regarding the withdrawal of Zantac from the market and the knowledge of its potential cancer-causing effects [1][2]. Group 1: Allegations and Legal Context - The class period for the lawsuit is from February 5, 2020, to August 14, 2022 [1]. - Allegations state that GSK misrepresented the reasons for removing Zantac, claiming it was based on available information and regulatory correspondence, while being aware of the source of NDMA for nearly 40 years [1]. - GSK assured investors that there was no causal link between ranitidine therapy and cancer, which was later found to be materially false or misleading [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased GSK shares during the class period are encouraged to register for the class action, with a deadline of April 7, 2025, to seek lead plaintiff status [2]. - Registered shareholders will receive updates through portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].